Bristol Centre for Antimicrobial Research and Evaluation, Department of Cellular and Molecular Medicine, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK.
J Antimicrob Chemother. 2010 Feb;65(2):179-82. doi: 10.1093/jac/dkp443. Epub 2009 Dec 14.
The strategy of decreasing antimicrobial prescribing to reduce existing antimicrobial resistance appears attractive, but its effectiveness, particularly in the community setting, remains unclear. Contrasting results obtained from the relatively few studies in this area confuse matters further. Prescribing reductions have successfully reduced the prevalence of resistance among respiratory pathogens, but in these cases single bacterial clones dominated the resistant population. In contrast, this strategy has not succeeded in reducing plasmid-encoded resistance among Escherichia coli. The reasons why some prescribing restriction policies are more successful than others are complex, with the three key determinants being the fitness cost of resistance, the clonal structure of the resistant bacterial population and co-selection of resistant organisms by other antimicrobials. The resistant bacterial phenotypes that are likely to be the easiest to eliminate will be those composed of relatively clonal populations that bear a fitness cost of resistance and are not significantly subjected to co-selection by other antimicrobials. Plasmid-encoded resistance seldom meets these criteria and, hence, is likely to be the most difficult to reduce.
减少抗菌药物处方以降低现有抗菌药物耐药性的策略似乎很有吸引力,但它的有效性,特别是在社区环境中,仍不清楚。这方面为数不多的研究得出的对比结果进一步混淆了问题。处方减少成功降低了呼吸道病原体的耐药率,但在这些情况下,单一的细菌克隆主导了耐药群体。相比之下,这一策略在减少大肠杆菌中的质粒编码耐药性方面并未成功。一些处方限制政策比其他政策更成功的原因很复杂,三个关键决定因素是耐药性的适应性成本、耐药细菌群体的克隆结构以及其他抗菌药物对耐药生物的共同选择。最容易消除的耐药细菌表型将是那些由相对克隆的群体组成的表型,这些群体具有耐药性的适应性成本,并且不受其他抗菌药物的共同选择的影响。质粒编码的耐药性很少符合这些标准,因此,很可能是最难减少的。